ANCA-Associated Vasculitis

  • John H. Stone
  • Shoichi Ozaki
  • Karina Keogh
  • Ulrich Specks
  • Carol A. Langford
  • Niels Rasmussen
  • Cees G. M. Kallenberg
  • Ingeborg M. Bajema


The majority of patients with Wegener's granulomatosis (WG) or microscopic polyangiitis (MPA) have antineu-trophil cytoplasmic antibodies (ANCA) in their serum. This is particularly true of patients with “disseminated” disease, the great majority of whom are ANCA positive. WG and MPA are often termed “ANCA-associated vasculitides” (AAV), even though not all patients with these conditions have ANCA. The Churg—Strauss syndrome, another disorder classified as an AAV, is discussed in Chap. 23. Multiple antibodies may lead to positive immunofluores-cence testing for ANCA in either perinuclear (P-ANCA) or cytoplasmic (C-ANCA) patterns. However, only antibodies to myeloperoxidase (MPO) and proteinase-3 (PR3) are associated with the A AV. Antibodies directed against PR3 and MPO are termed PR3-ANCA and MPO-ANCA, respectively. WG may be associated with destructive upper respiratory tract disease, including saddle-nose deformity, erosive sinusitis, and subglottic stenosis. A host of ocular lesions may occur in the A AV, including episcleritis, scleritis, peripheral ulcerative keratitis, and orbital pseudotumor. Most of these lesions are more common in WG than in MPA. Lung disease in the AAV ranges from nodular lesions with a tendency to cavitate (in WG), to interstitial lung disease (MPA), and to alveolar hemorrhage (both WG and MPA). Segmental, necrotizing glomerulonephritis commonly accompanies the AAV. Because of the paucity of immunoreactants such as immunoglobulins and complement components in kidney biopsies relative to the biopsies from patients with immune complex-mediated glomerulonephritis, the glomerulonephritis of the A AV is termed “pauci-immune.”


Giant Cell Arteritis Alveolar Hemorrhage Disease Flare Fibrinoid Necrosis Subglottic Stenosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Antineutrophil cytoplasmic autoantibody-associated pauci-immune glomerulonephritis and vasculitis, and other vasculitides. In: D'Agati VD, Jennette JC, Silva FG (eds) Non-neoplastic kidney diseases (1st edn). Silver Spring, MD, ARP, 2005, pp. 385–424Google Scholar
  2. Bajema IM, Bruijn JA. What stuff is this! A historical perspective on fibrinoid necrosis. J Pathol 2000; 191:235–238PubMedCrossRefGoogle Scholar
  3. Bean SM, Conner MG. Wegener's granulomatosis of the uterine cervix: A case report and review of the literature. Int J Gynecol Pathol 2007; 26:95–98PubMedCrossRefGoogle Scholar
  4. Bienaime F, Clerbaux G, et al D-Penicillamine-induced ANCA-associated crescentic glomerulonephritis in Wilson disease. Am J Kidney Dis 2007; 50(5):821–825PubMedCrossRefGoogle Scholar
  5. Birnbaum J, Danoff S, Askin FB, Stone JH. Microscopic polyangiitis presenting as a ‘pulmonary-muscle’ syndrome: Does alveolar hemorrhage contribute to the mechanism of pulmonary fibrosis?. Arthritis Rheum 2007; 56(6):20–71CrossRefGoogle Scholar
  6. Boomsma MM, Stegeman CA, van der Leij MJ, et al Prediction of relapses in Wegener's granulomatosis by measurement of antineu-trophil cytoplasmic antibody levels. A prospective study. Arthritis Rheum 2000; 43:2025–2033PubMedCrossRefGoogle Scholar
  7. Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic antibodies. Lancet 2006; 368:404–418PubMedCrossRefGoogle Scholar
  8. Brons RH, de Jong MC, de Boer NK, et al Detection of immune deposits in skin lesions of patients with Wegener's granulomatosis. Ann Rheum Dis 2001; 60:1097–1102PubMedCrossRefGoogle Scholar
  9. Carrington CB, Liebow A. Limited forms of angiitis and granulomato-sis of Wegener's type. Am J Med 1966; 41:497–527PubMedCrossRefGoogle Scholar
  10. D'Cruz DP, Baguley E, Asherson RA, et al Ear, nose, and throat symptoms in subacute Wegener's granulomatosis. BMJ 1989; 299: 419–422PubMedCrossRefGoogle Scholar
  11. Devaney KO, Travis WD, Hoffman G, et al Interpretation of head and neck biopsies in Wegener's granulomatosis. A pathologic study of 126 biopsies in 70 patients. Am J Surg Pathol 1990; 14:555–564PubMedCrossRefGoogle Scholar
  12. Duggan CP, Westra SJ, Rosenberg AE. Case records of the Massachusetts General Hospital. Case 23–2007. A 9-year-old boy with bone pain, rash, and gingival hypertrophy. N Engl J Med 2007; 357:392–400PubMedCrossRefGoogle Scholar
  13. Eisenberger U, Fakhouri F, Vanhille P, et al ANCA-negative pauci-immune renal vasculitis: histology and outcome. Nephrol Dial Transplant 2005; 20:1392–1399PubMedCrossRefGoogle Scholar
  14. Eschun GM, Mink SN, Sharma S. Pulmonary interstitial fibrosis as a presenting manifestation in perinuclear antineutrophilic cytoplas-mic antibody microscopic polyangiitis. Chest 2003; 123:297–301PubMedCrossRefGoogle Scholar
  15. FDA Public Health Notification: Complications from metallic tracheal stents in patients with benign airway disorders.
  16. Feriozzi S, Muda AO, et al Cephotaxime-associated allergic interstitial nephritis and MPO-ANCA positive vasculitis. Ren Fail 2000; 22(2):245–251PubMedCrossRefGoogle Scholar
  17. Finkielman JD, Lee AS, Hummel AM, et al ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. Am J Med 2007; 120:643.e9–e14PubMedGoogle Scholar
  18. Finkielman JD, Merkel PA, Schroeder D, et al for the WGET Research Group. Antineutrophil cytoplasmic antibodies against proteinase 3 do not predict disease relapses in Wegener's granulomatosis. Ann Intern Med 2007 147(9):611–9PubMedCrossRefGoogle Scholar
  19. Franssen C, Gans R, Kallenberg C, et al Disease spectrum of patients with antineutrophil cytoplasmic autoantibodies of defined specificity: Distinct differences between patients with anti-proteinase 3 and anti-myeloperoxidase autoantibodies. J Intern Med 1998 244:209–216PubMedCrossRefGoogle Scholar
  20. Gallagher H, Kwan JT, Jayne DR. Pulmonary renal syndrome: A 4-year, single-center experience. Am J Kidney Dis 2002; 39:42–47PubMedCrossRefGoogle Scholar
  21. Geetha D, Seo P. Renal transplantation in the ANCA-associated vascu-litides. Am J Transplant 2007; 7:2657–2662PubMedCrossRefGoogle Scholar
  22. Geffriaud-Ricouard C, Noël LH, Chauveau D. Clinical significance of ANCA in 98 patients. Adv Exp Med Biol 1993; 336:273–279PubMedGoogle Scholar
  23. Genereau T, Lortholary O, Pottier M, et al Temporal artery biopsy. A diagnostic tool for systemic necrotizing vasculitis. Arthritis Rheum 1999; 42:2674–2681PubMedCrossRefGoogle Scholar
  24. Gera M, Griffin MD, Specks U, et al Recurrence of ANCA-associated vasculitis following renal transplantation in the modern era of immunosupression. Kidney Int 2007; 71:1296–1301PubMedCrossRefGoogle Scholar
  25. Goek ON, Stone JH. Randomized controlled trials in ANCA-associated vasculitis. Curr Opin Rheumatol 2005; 17:257–264PubMedCrossRefGoogle Scholar
  26. Guillevin L, Durand-Gasselin B, Cevallos R. Microscopic polyangiitis: Clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999; 42:421–430PubMedCrossRefGoogle Scholar
  27. Gunton JE, Stiel J, et al Prevalence of positive anti-neutrophil cytoplas-mic antibody (ANCA) in patients receiving anti-thyroid medication. Eur J Endocrinol 2000; 142(6):587CrossRefGoogle Scholar
  28. Haas M, Eustace JA. Immune complex deposits in ANCA-associated crescentic glomerulonephritis: A study of 126 cases. Kidney Int 2004; 65:2145–2152PubMedCrossRefGoogle Scholar
  29. Harris AA, Falk RJ, Jennette JC. Crescentic glomerulonephritis with a paucity of glomerular immunoglobulin localization. Am J Kidney Dis 1998; 32:179–184PubMedCrossRefGoogle Scholar
  30. Haubitz M et al Cyclophosphamide phramacokinetics and dose requirements in patients with renal insufficiency. Kidney Int 2002; 61: 1495–1501PubMedCrossRefGoogle Scholar
  31. Hauer HA, Bajema IM, de Heer E, et al Distribution of renal lesions in idiopathic systemic vasculitis: A three-dimensional analysis of 87 glomeruli. Am J Kidney Dis 2000; 36:257–265PubMedCrossRefGoogle Scholar
  32. Hauer HA, Bajema IM, van Houwelingen HC, et al Renal histology in ANCA-associated vasculitis: Differences between diagnostic and serologic subgroups. Kidney Int 2002; 61:80–89PubMedCrossRefGoogle Scholar
  33. Hoffman G, Kerr G, Leavitt R, et al Wegener's granulomatosis: An analysis of 158 patients. Ann Intern Med 1992; 116:488–498PubMedCrossRefGoogle Scholar
  34. Holvast A, Stegeman CA, Benne CA, et al Wegener's granulomatosis patients show an adequate antibody response to influenza vaccination. Ann Rheum Dis 2008 July 14. [Epub ahead of print]Google Scholar
  35. Hollander D, Manning RT. The use of alkylating agents in the treatment of Wegener's granulomatosis. Ann Intern Med 1967; 67:393–8PubMedCrossRefGoogle Scholar
  36. Homma S, Matsushita H, Nakata K. Pulmonary fibrosis in myeloper-oxidase antineutrophil cytoplasmic antibody-associated vasculiti-des. Respirology 2004; 9(2):190–196PubMedCrossRefGoogle Scholar
  37. Javaud N, Belenfant X, Stirnemann J, et al Renal granulomatoses: A retrospective study of 40 cases and review of the literature. Medicine (Baltimore) 2007; 86:170–180CrossRefGoogle Scholar
  38. Jayne D, Rasmussen N, Bacon, et al Randomised trial of cyclo-phosphamide versus azathioprine during remission in ANCA-associated systemic vasculitis. N Engl J Med 2003; 349: 36–44PubMedCrossRefGoogle Scholar
  39. Jayne DR, Gaskin G, Pusey CD, Lockwood CM. ANCA and predicting relapse in systemic vasculitis. QJM 1995; 88:127–133PubMedGoogle Scholar
  40. Jayne DR, Gaskin G, Pusey CD, Lockwood CM. ANCA and predicting relapse in systemic vasculitis. QJM 1995; 88:127–133PubMedCrossRefGoogle Scholar
  41. Kyndt et al Serial measurements of antineutrophil cytoplasmic autoan-tibodies in patients with systemic vasculitis. Am J Med 1999; 106:527–533CrossRefGoogle Scholar
  42. Langford C, Talar-Williams C, Barron K, et al A staged approach to the treatment of Wegener's granulomatosis: Induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 1999; 42: 2666–2673PubMedCrossRefGoogle Scholar
  43. Leavitt RY, Fauci AS, Bloch DA, et al The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990; 33:1101–1107PubMedCrossRefGoogle Scholar
  44. Luqmani RA, Bacon PA, Beaman, et al Classical versus non-renal Wegener's granulomatosis. Q J Med 1994; 87:161–167PubMedGoogle Scholar
  45. Mahr AD, Neogi T, LaValley MP, et al Assessment of the item selection and weighting in the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) (submitted)Google Scholar
  46. Merkel PA, Lo GH, Holbrook JT, et al for the WGET Research Group. Incidence of venous thrombotic events among patients with Wegener's granulomatosis. Ann Intern Med 2005; 142:620–626PubMedCrossRefGoogle Scholar
  47. Nachman PH, Hogan SL, Jennette JC, Falk RJ. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996; 7(1):33–9PubMedGoogle Scholar
  48. Nachman PH, Segelmark M, Westman K, et al Recurrent ANCA-associated small vessel vasculitis after transplantation: A pooled analysis. Kidney Int 1999; 56:1544–1550PubMedCrossRefGoogle Scholar
  49. Nasr SH, D'Agati VD, Park, et al Necrotizing and crescentic lupus nephritis with antineutrophil cytoplasmic antibody seropositivity. Clin J Am Soc Nephrol 2008; 3:682–690PubMedCrossRefGoogle Scholar
  50. Niles JL, Böttinger EP, Saurina GR, et al The syndrome of lung hemorrhage and nephritis is usually an ANCA-associated condition. Arch Intern Med 1996; 156:440–445PubMedCrossRefGoogle Scholar
  51. Polychronopoulos VS, Prakash UB, Golbin JM, et al Airway involvement in Wegener's granulomatosis. Rheum Dis Clinics N America 2007; 33:755–775CrossRefGoogle Scholar
  52. Reinhold-Keller E, Beuge N, Latza U, et al An interdisciplinary approach to the care of patients with Wegener's granulomatosis. Long term outcome in 155 patients. Arthritis Rheum 2000; 43(5):1021–1032PubMedCrossRefGoogle Scholar
  53. Robinson MR, Lee SS, Sneller MC, et al Tarsal-conjunctival disease associated with Wegener's granulomatosis. Ophthalmology 2003; 110:1770–1780PubMedCrossRefGoogle Scholar
  54. Rostaing L, Modesto A, Oksman F et al Outcome of patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis following cadaveric kidney transplantation. Am J Kidney Dis 1997; 29(1):96–102PubMedCrossRefGoogle Scholar
  55. Sadiq Z, Shepherd R, Vardy S. Posterior scleritis: An unusual presentation of facial pain. Br J Oral Maxillofac Surg 2003; 41:62–63PubMedCrossRefGoogle Scholar
  56. Sakai N, Wada T, et al Tubulointerstitial nephritis with anti-neutrophil cytoplasmic antibody following indomethacin treatment. Nephrol Dial Transplant 1999; 14(11):2774CrossRefGoogle Scholar
  57. Saxena R, Bygren P, Arvastson B, Wieslander J. Circulating autoanti-bodies as serological markers in the differential diagnosis of pulmonary renal syndrome. J Intern Med 1995; 238:43–52CrossRefGoogle Scholar
  58. Slot MC, Links TP, et al Occurrence of antineutrophil cytoplasmic antibodies and associated vasculitis in patients with hyperthyroidism treated with antithyroid drugs: A long-term followup study. Arthritis Rheum 2005; 53(1):108–113PubMedCrossRefGoogle Scholar
  59. Small P, Brisson M-L. Wegener's granulomatosis presenting as temporal arteritis. Arthritis Rheum 1991; 34:220–223PubMedCrossRefGoogle Scholar
  60. Sneller MC, Hoffmann GS, Talar-Williams C, et al An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995; 38:608–613PubMedCrossRefGoogle Scholar
  61. Specks U et al Design of the rituximab in ANCA-associated vasculitis (RAVE) trial. 2009 (in press)Google Scholar
  62. Stassen PM, Sanders JS, Kallenberg CG, Stegeman CA. Influenza vaccination does not result in an increase in relapses in patients with ANCA-associated vasculitis. Nephrol Dial Transplant 2008; 23:654–658PubMedCrossRefGoogle Scholar
  63. Stassen PM, Derks RPH, Kallenberg CGM, Stegeman CA. Thiopurinemethyltransferase (TPMT) genotype and TPMT activity in patients with anti-neutrophil cytoplasmic antibody-associated vas-culitis: relation to azathioprine maintenance treatment and adverse effects. Ann Rheum Dis Ann Rheum Dis 2009; 68(5):758–9CrossRefGoogle Scholar
  64. Stegeman CA, Cohen Tervaert JW, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CGM. Association of nasal carriage of Staphylococcus aureus and higher relapse in Wegener's Granulomatosis. Ann Intern Med 1994; 120:12–17PubMedCrossRefGoogle Scholar
  65. Stegeman CA. Anti-neutrophil cytoplasmic antibody (ANCA) levels directed against proteinase-3 and myeloperoxidase are helpful in predicting disease relapse in ANCA-associated small-vessel vasculi-tis. Nephrol Dial Transplant 2002; 17(12):2077–80PubMedCrossRefGoogle Scholar
  66. Stone J, Millward C, Criswell L. Two Unusual Genitourinary Manifestations Of Wegener's Granulomatosis. The Journal of Rheumatology 1997; 24(11): 1846–1848PubMedGoogle Scholar
  67. Stone JH: and the Wegener's Granulomatosis Etanercept Trial Research Group. Limited versus severe Wegener's granulomatosis: Baseline data on patients in the Wegener's granulomatosis etanercept trial. Arthritis Rheum 2003; 48:2299–2309PubMedCrossRefGoogle Scholar
  68. Stone JH, Hoffman GS, Wegener's Granulomatosis. In: Hochberg MC, Smolen JS, Weinblatt ME, Weisman MH (eds) Rheumatology (4th edn). London, Elsevier, 2006, pp. 72.1–72.25Google Scholar
  69. Suryaprasad A, Stone JH. When is it safe to stop Pneumocystis carinii (jiroveci) prophylaxis? Insights from cases complicating autoimmune diseases. Arthritis Care & Research 2008; 59(7):1034–9CrossRefGoogle Scholar
  70. The WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials 2002; 23: 450–468CrossRefGoogle Scholar
  71. The WGET Research Group. Etanercept plus standard therapy in patients with wegener's granulomatosis. N Engl J Med 2005; 352:351–361CrossRefGoogle Scholar
  72. Wainright J, Davson J. The renal appearances in the microscopic form of periarteritis nodosa. J Pathol Bacteriol 1950; 62:189–196CrossRefGoogle Scholar
  73. Wegener F. Uber generalisierte, septische Gefasserkrankungen. Verh Dtsch Ges Pathol 1936; 29:202Google Scholar
  74. Wegener F. Über eine eigenartige rhinogene Granulomatose mit beson-derer Beteiligung des Arteriensystems und der Nieren. Beitr Pathol 1939; 102:36Google Scholar
  75. Wiesner O, Russell KA, Lee AS, et al Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastase as a diagnostic marker for cocaine-induced midline destructive lesions but not autoimmune vasculitis. Arthritis Rheum 2004; 50:2954–2965PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • John H. Stone
    • 1
  • Shoichi Ozaki
    • 2
  • Karina Keogh
    • 3
  • Ulrich Specks
    • 3
  • Carol A. Langford
    • 4
  • Niels Rasmussen
    • 5
  • Cees G. M. Kallenberg
    • 6
  • Ingeborg M. Bajema
    • 7
  1. 1.Massachusetts General HospitalBoston
  2. 2.St. Marianna University School of Medicine Department of Internal Medicine 2-16-1 SugaoMiyamae-kuJapan
  3. 3.Division of Pulmonary and Critical Care Medicine, May ClinicRochesterUSA
  4. 4.Cleveland Clinic Foundation, Department of Rheumatology & ImmunologyClevelandUSA
  5. 5.Rigshospitalet, Otolaryngology — Head and Neck SurgeryBlegdamsvej 9Denmark
  6. 6.University Medical Groningen Clinical Immunology/Rheumatology T3 242 Hanzeplein 1GroningenThe Netherlands
  7. 7.Department of Pathology, Leiden University Medical CenterLeidenThe Netherlands

Personalised recommendations